Close

Share this page

India

We established our Indian operations in 2010. The country boasts one of the largest concentrations of biotech companies in the world. The government wants to expand on this, aiming to increase the number of companies from the present 500 to 2,000 by 2020 by investing US$146.7 million. The government has also been collaborating with Australia on clinical research via the Indo-Australian Boosting Gold Fellowship. By the end of 2017, the biotech market is expected to grow to US$11.6 billion.


Fast Facts

Health Expenditure per Capita
(2014, US$)

$75

Source: World Health Organization Global Health Expenditure Database

Life Expectancy at Birth
(2016 est.)

male

67

years

female

69

years

Source: The World Fact Book;
Central Intelligence Agency

Burden of Disease DALYs Causes % of Total DALYs
(2015, all ages/both sexes)

Ischemic heart disease (7.28%)

Neonatal preterm birth
complication (5.48%)

Neonatal encephalopathy due to
birth asphyxia and trauma (4.91%)

Source: Global Burden of Disease Study 2015;
Institute for Health Metrics and Evaluation

NDA Approval Time

12

months



18

months




Features

India's regulatory reforms for clinical trials

Due to low costs and a large patient population, India was previously considered a top-tier location for clinical trials. However, India’s limited infrastructure and less-efficient regulations have resulted in many ...

The role of the Clinical Trials Registry – India (CTRI)

The Clinical Trials Registry - India (CTRI) is hosted at the National Institute of Medical Statistics in the Indian Council of Medical Research. Launched in July 2007, the CTRI is a FREE online portal for the recording and publishing ...


Services Available in India

c/o Singapore office

c/o Singapore office: 150 Beach Road #06-03/04 The Gateway West Singapore 189720
Tel: +65 6294 1678
Fax: +65 6294 0678
E-mail: info@epsi-global.com


We will tailor an ideal solution for your specific needs.

Request a Proposal